In  acyl leukotriene (LTC4, LTD4 and LTE4) by including the mast cells and eosinophils cells release a strong inflammatory effect of eicosane, before these important asthma with found in human airway inflammatory mediators in acyl leukotriene receptor (CysLT), leading to a variety of airway responses, including bronchoconstriction, mucus secretion, increased vascular permeability, and eosinophils.

Monteluster sodium is an effective oral selective antagonist of leukotrienes receptor, which can specifically inhibit cysteamine leukotrienes receptor. It was successfully developed by Merck of Germany and listed in Canada, Finland and Mexico in 1997. For adults and children asthma prevention and treatment for a long time, including the prevention of asthma symptoms of day and night, sensitive to aspirin treatment of asthma and to prevent movement of bronchoconstriction, can also be used to alleviate the age of 15 and 15 years of age or older patients resistant to other treatment is invalid or not seasonal allergic rhinitis symptoms.